Stockscreener 앱 받기
12.15
4.26%
0.41
Amarin Corp Adr 주식(AMRN)의 최신 뉴스
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin Takes Critical Step to Avoid Nasdaq Delisting with 1-for-20 Share Consolidation - Stock Titan
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Major Shake-up: Investment Firm Leader Joins Amarin Board to Drive Shareholder Value - Stock Titan
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
A Look at New Gold Inc (NGD) Shares in the Recent Past Indicates Growth - Sete News
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Assessing the Risk and Potential of Sempra’s (SRE) Stock - The News Heater
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding Globally - GuruFocus
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript - The Motley Fool
Amarin announce splan to initiate ratio change under ADR program - TipRanks
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - The Manila Times
Amarin Corp. (AMRN) Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing - StreetInsider.com
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - StockTitan
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Will Amarin's Q4 Earnings Mark a Turning Point? Key Date and Details Revealed - Stock Titan
Amarin Corp ADR (AMRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Amarin Corp ADR [AMRN] Stock bought by Insider Berg Aaron for $0.1 million - Knox Daily
Ratios Uncovered: Breaking Down Amarin Corp ADR (AMRN)’s Trailing Twelve Months Metrics - The Dwinnex
Checking in on Indivior Plc (INDV) after recent insiders movement - Knox Daily
Ratios Uncovered: Breaking Down Neuronetics Inc (STIM)’s Trailing Twelve Months Metrics - The Dwinnex
Are Smart Investors Making the Right Decision? Amarin Corp ADR (AMRN) - SETE News
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Stocks of Talen Energy Corp (TLN) are poised to climb above their peers - SETE News
Scholar Rock Holding Corp (SRRK) requires closer examination - US Post News
Amarin Corp ADR (AMRN) shows promising results - US Post News
Analysts review Amarin Corp ADR’s rating - Knox Daily
ALLY’s latest rating updates from top analysts. - Knox Daily
Ratio Review: Analyzing Caleres Inc (CAL)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Financial Health Report: Tevogen Bio Holdings Inc (TVGN)’s Ratios Tell a Tale - The Dwinnex
Financial Metrics Exploration: Understanding Opendoor Technologies Inc (OPEN) Through Ratios - The Dwinnex
Potential Price Increase for Godaddy Inc (GDDY) After Recent Insider Activity - Knox Daily
Analyzing Ratios: Amarin Corp ADR (AMRN)’s Financial Story Unveiled - The Dwinnex
Establishment Labs Holdings Inc (ESTA) expanding its growth trajectory ahead - SETE News
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Amarin stock touches 52-week low at $0.45 amid challenges - Investing.com
Italy grants VAZKEPA reimbursement for heart risk - Investing.com
Amarin Corporation plc (ADR) : Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG) - Marketscreener.com
Amarin appoints new chief financial officer - Investing.com
Amarin Appoints Peter Fishman Chief Financial Officer - GlobeNewswire Inc.
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin stock touches 52-week low at $0.55 amid market challenges - Investing.com
Earnings call: Amarin reports Q3 revenue dip amid U.S. generic competition - Investing.com
Amarin stock plunges to 52-week low of $0.56 amid market challenges - Investing.com
Amarin stock touches 52-week low at $0.57 amid challenges - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results - Yahoo Finance
Why Pharma Company Amarin Shares Are Zooming Today - Markets Insider
GSK Gears Up to Report Q1 Earnings: What's in the Cards? - Nasdaq
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China - Yahoo Finance
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations - Benzinga
The Week Ahead In Biotech: Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing - Yahoo Finance
AMRNAmarin Latest Stock News & Market Updates - Stock Titan
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval - MarketWatch
Cramer Advises His Viewers On GW Pharma, Enphase And More - Benzinga
0.15%
0.51%
자본화:
|
볼륨(24시간):